Top Page
Cambridge Cognition Holdings
(LSE:COG)
Cambridge Cognition Holdings (COG) vs. iShares MSCI United Kingdom ETF (EWC)
Cambridge Cognition Holdings Business Overview & Revenue Model
Cambridge Cognition Holdings Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.05M | 10.34M | 13.52M | 12.61M | 10.09M | 6.74M |
| Gross Profit | 7.25M | 8.39M | 10.80M | 9.32M | 8.08M | 5.42M |
| EBITDA | -563.00K | -542.00K | -2.62M | -514.00K | 412.00K | -502.00K |
| Net Income | -1.67M | -1.78M | -3.51M | -409.00K | 450.00K | -438.00K |
Balance Sheet | ||||||
| Total Assets | 11.73M | 13.03M | 14.23M | 15.11M | 12.54M | 6.26M |
| Cash, Cash Equivalents and Short-Term Investments | 428.00K | 1.30M | 3.23M | 8.32M | 6.81M | 3.05M |
| Total Debt | 1.48M | 1.91M | 2.56M | 18.00K | 18.00K | 98.00K |
| Total Liabilities | 9.40M | 9.67M | 12.95M | 15.01M | 11.91M | 6.21M |
| Stockholders Equity | 2.33M | 3.36M | 1.28M | 95.00K | 632.00K | 57.00K |
Cash Flow | ||||||
| Free Cash Flow | -1.76M | -3.09M | -5.00M | 1.49M | 3.88M | 972.00K |
| Operating Cash Flow | -1.75M | -3.08M | -4.97M | 1.68M | 3.93M | 1.01M |
| Investing Cash Flow | 30.00K | 50.00K | -3.02M | -189.00K | -105.00K | -42.00K |
| Financing Cash Flow | -1.15M | 1.13M | 2.88M | -132.00K | -86.00K | 1.16M |
Cambridge Cognition Holdings Technical Analysis
Cambridge Cognition Holdings Peers Comparison
Cambridge Cognition Holdings Corporate Events
Cambridge Cognition Holdings has issued 589,287 new ordinary shares following the exercise of share options, increasing its total to 46,629,700 shares. This move is part of the company’s strategy to enhance its market presence and shareholder value, aligning with its focus on expanding its digital health products in the brain health sector.
The most recent analyst rating on (GB:COG) stock is a Hold with a £32.00 price target. To see the full list of analyst forecasts on Cambridge Cognition Holdings stock, see the GB:COG Stock Forecast page.
Cambridge Cognition Holdings has announced a live presentation of its Interim Results, to be conducted by Rob Baker and Ronald Openshaw, on 03 September 2025. This presentation, accessible to all existing and potential shareholders, highlights the company’s commitment to transparency and engagement with stakeholders, potentially impacting its market positioning positively.
The most recent analyst rating on (GB:COG) stock is a Hold with a £32.00 price target. To see the full list of analyst forecasts on Cambridge Cognition Holdings stock, see the GB:COG Stock Forecast page.
Cambridge Cognition Holdings has successfully raised approximately £1.12 million through a placing and subscription of new ordinary shares, aimed at strengthening its working capital and balance sheet. This fundraising effort reflects strong shareholder support, with key stakeholders subscribing at a premium to the market price, indicating confidence in the company’s value and future profitability.
The most recent analyst rating on (GB:COG) stock is a Hold with a £25.00 price target. To see the full list of analyst forecasts on Cambridge Cognition Holdings stock, see the GB:COG Stock Forecast page.
Cambridge Cognition Holdings has announced significant changes to its board and management, marking a new phase in its development. Rob Baker has been appointed as Senior Executive Director, while Alex Livingstone-Learmonth and Ronald Openshaw are proposed to join the board, pending due diligence. These leadership updates are part of a strategic effort to enhance the company’s performance, with a focus on sales and operational achievements. The changes are expected to strengthen the company’s executive team, improve corporate governance, and support its vision of delivering shareholder value and improving patient lives.
The most recent analyst rating on (GB:COG) stock is a Hold with a £25.00 price target. To see the full list of analyst forecasts on Cambridge Cognition Holdings stock, see the GB:COG Stock Forecast page.
Cambridge Cognition Holdings plc reported significant growth in new sales orders and an expanded order book in its unaudited interim results for the first half of 2025. Despite a slight decrease in revenue, the company made substantial operational progress, launching new services and achieving regulatory milestones, such as submitting an FDA Letter of Intent for a digital cognitive assessment tool. The company also announced board and management changes and proposed financing to strengthen its working capital, indicating a strategic focus on long-term growth and profitability.
The most recent analyst rating on (GB:COG) stock is a Hold with a £25.00 price target. To see the full list of analyst forecasts on Cambridge Cognition Holdings stock, see the GB:COG Stock Forecast page.
Cambridge Cognition Holdings announced significant growth in new sales orders and an expanded order book in its unaudited interim results for the first half of 2025. The company has made substantial operational progress, including supporting numerous international clinical studies and launching new service offerings like in-house Rater Training and Automated Quality Assurance. Additionally, Cambridge Cognition achieved regulatory milestones by submitting a Letter of Intent to the FDA for a digital cognitive assessment tool for schizophrenia and gained recognition through landmark studies with major pharmaceutical companies. The company is also pursuing partnerships in the healthcare and consumer health markets to broaden its offerings.
The most recent analyst rating on (GB:COG) stock is a Hold with a £25.00 price target. To see the full list of analyst forecasts on Cambridge Cognition Holdings stock, see the GB:COG Stock Forecast page.
Cambridge Cognition Holdings announced that Monument Therapeutics, in which it holds a 20% stake, has partnered with the Foundation for the National Institutes of Health to conduct a clinical trial for MT1988, a novel treatment for cognitive impairment associated with schizophrenia. This collaboration is part of the Accelerating Medicines Partnership Schizophrenia program, which aims to develop more effective treatments for schizophrenia. The trial highlights the value of Cambridge Cognition’s digital assessment technology and reinforces the company’s strategy of targeting areas with high unmet clinical needs, offering potential long-term value through equity and royalty interests.
Cambridge Cognition Holdings has launched a proprietary speaker identification solution aimed at preventing duplicate participant enrolment in clinical trials, a significant issue affecting data integrity and study validity. This solution, which is part of the company’s AI voice-enabled data quality management tools, has already secured initial commercial deals and is expected to be deployed by a major pharmaceutical client in Q4 2025, reflecting the company’s strategic commitment to enhancing reliability and efficiency in clinical research.
Cambridge Cognition Holdings reported significant growth in new sales orders and an increased order book for the first half of 2025, despite a decline in revenue compared to the previous year. The company is optimistic about future revenue growth and profitability, driven by a strong pipeline of opportunities and strategic expansion into healthcare and consumer health markets. However, the cancellation of two clinical studies will impact cash generation in the second half of the year. The company remains focused on building its order book and expanding its presence in professional healthcare and consumer health markets.